Table 2.
Baseline demographic characteristics of the study population.
| Variable | Overall | D-Hep | D-Cirr | ND-Hep | ND-Cirr |
|---|---|---|---|---|---|
| CD3+ T%, M (Q1, Q3) |
76.1 (70.3–78.5) | 76.1 (75.9–76.3) | 76.7 (73.5–78.1) | 75.1 (69.7–78.8) | 72.6 (66.2–79.2) |
| CD3+ T, M (Q1, Q3) |
1,562.5 (1,200.3–1,844.3) | 1,686.0 (1,673.0–1,709.0) | 1,340.0 (1,230.5–1,584.5) | 1,529.5 (1,198.5–1,983.3) | 1,245.0 (766.0–1,726.3) |
| CD4+/CD45+, M (Q1, Q3) |
43.0 (39.0–49.0) | 43.0 (43.0–43.0) | 45.0 (39.5–49.0) | 44.0 (38.0–49.3) | 44.0 (37.3–48.0) |
| CD4+ CD8+/CD45+, M (Q1, Q3) |
0.2 (0.1–0.4) | 0.2 (0.2–0.2) | 0.2 (0.1–0.4) | 0.3 (0.1–0.4) | 0.2 (0.1–0.4) |
| CD4+/CD8+ T, M (Q1, Q3) |
4.0 (2.0–8.0) | 4.0 (4.0–4.0) | 3.0 (2.0–8.0) | 4.0 (2.0–9.0) | 4.0 (2.0–8.8) |
| CD4+ T, M (Q1, Q3) |
909.5 (678.3–1,081.0) | 948.5 (911.0–962.0) | 809.0 (631.0–953.5) | 883.5 (684.3–1,162.8) | 738.5 (438.3–1,024.5) |
| CD45+ _lymph, M (Q1, Q3) |
2,086.0 (1,646.3–2,469.3) | 2,217.5 (2,134.0–2,318.0) | 1,895.0 (1,711.5–2,047.0) | 2,063.0 (1,656.8–2,607.0) | 1,673.5 (1,115.8–2,232.0) |
| CD8+/CD45+, M (Q1, Q3) |
26.5 (21.0–30.0) | 27.0 (27.0–27.0) | 26.0 (22.0–29.0) | 26.0 (20.3–31.0) | 24.0 (19.9–28.8) |
| CD8+ T, M (Q1, Q3) |
546.0 (366.0–655.5) | 605.5 (568.0–621.0) | 478.0 (349.5–573.5) | 529.0 (377.0–679.5) | 367.0 (270.3–625.5) |
| Th/Ts(CD4+/CD8+), M (Q1, Q3) |
1.7 (1.4–2.2) | 1.7 (1.7–1.7) | 1.8 (1.5–2.1) | 1.7 (1.3–2.3) | 1.8 (1.4–2.4) |
| TBIL, M (Q1, Q3) |
13.0 (9.6–17.6) | 12.0 (9.0–16.1) | 16.0 (10.7–23.4) | 12.9 (9.2–16.9) | 15.4 (11.4–23.2) |
| ALB, M (Q1, Q3) |
42.0 (39.5–44.8) | 42.9 (40.9–45.9) | 42.0 (38.7–44.3) | 42.0 (39.7–44.4) | 41.0 (37.6–44.0) |
| DBIL, M (Q1, Q3) |
4.4 (3.0–6.2) | 4.6 (3.3–6.1) | 5.2 (3.4–10.1) | 4.0 (2.9–5.7) | 5.6 (3.0–8.3) |
| ALP, M (Q1, Q3) |
66.0 (54.0–87.0) | 65.0 (54.0–84.0) | 82.0 (62.5–101.5) | 65.0 (53.0–85.0) | 70.0 (55.3–98.8) |
| HCT, M (Q1, Q3) |
42.1 (38.6–45.4) | 43.2 (40.5–45.5) | 41.8 (39.2–46.3) | 42.0 (38.7–45.7) | 40.2 (35.4–43.6) |
| CHE, M (Q1, Q3) |
7,878.5 (6,489.0–8,772.8) | 7,942.5 (6,836.0–8,663.0) | 7,374.0 (5,802.0–8,452.0) | 7,895.5 (6,984.5–8,949.3) | 6,552.0 (4,405.3–8,483.8) |
| ADA, M (Q1, Q3) |
18.9 (14.0–25.9) | 15.5 (11.0–22.0) | 23.4 (18.8–33.5) | 18.9 (14.0–25.4) | 22.5 (18.0–28.0) |
| PLT, M (Q1, Q3) |
159.0 (115.0–204.0) | 185.0 (141.0–226.0) | 105.0 (77.5–176.0) |
164.0 (128.8–206.0) | 102.0 (67.3–163.3) |
| HGB, M (Q1, Q3) |
143.5 (130.0–155.0) | 148.5 (140.0–155.0) | 142.5 (132.0–155.5) | 143.0 (131.0–157.0) | 135.0 (117.3–148.8) |
| ALT, M (Q1, Q3) |
31.2 (15.6–63.3) | 36.4 (17.7–64.2) | 40.7 (16.5–71.5) | 32.3 (15.5–66.6) | 25.1 (16.6–44.1) |
| GGT, M (Q1, Q3) |
41.8 (23.2–87.9) | 39.8 (21.1–88.0) | 54.0 (30.9–184.8) | 41.8 (23.9–84.5) | 38.3 (21.5–81.7) |
| AST, M (Q1, Q3) |
30.0 (20.4–52.8) | 34.0 (20.0–54.0) | 37.2 (22.9–66.4) | 30.0 (20.4–52.5) | 27.6 (21.4–49.5) |